Pappas Capital LLC
07/01/2014 | Press release | Archived content
Ultragenyx Announces Initiation of a Phase 2 Study of KRN23 for P...
News | 07. 01. 2014
Ultragenyx Pharmaceutical
NOVATO, CA - July 1, 2014 - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the first patient screened and enrolled in the Phase 2 study of the human monoclonal anti-FGF23 antibody KRN23 (UX023) in pediatric patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness.
Pappas Capital LLC published this content on July 01, 2014, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]